Objective: This study was performed to determine whether gaps in patient flow from initial lung imaging to computed tomography (CT) guided lung biopsy in patients with nonesmall cell lung cancer (NSCLC) was associated with a change in tumour size, stage, and thus prognosis. Methods: All patients who had a CT-guided lung biopsy in 2009 (phase I) and in 2011 (phase II) with a pathologic diagnosis of primary lung cancer (NSCLC) at Eastern Health, Newfoundland, were identified. Dates of initial abnormal imaging, confirmatory CT (if performed), and CT-guided biopsy were recorded, along with tumour size and resulting T stage at each time point. In 2010, wait times for diagnostic imaging at Eastern Health were reduced. The stage and prognosis of NSCLC in 2009 was compared with 2011. Results: In phase 1, there was a statistically significant increase in tumour size (mean difference, 0.67 cm; P < .0001) and stage (P < .0001) from initial image to biopsy. There was a moderate correlation between the time (in days) between the images and change in size (r ¼ 0.33, P ¼ .008) or stage (r ¼ 0.26, P ¼ .036). In phase II, the median wait time from initial imaging to confirmatory CT was reduced to 7.5 days (from 19 days). At this reduced wait time, there was no statistically significant increase in tumour size (mean difference, 0.02; P > .05) or stage (P > .05) from initial imaging to confirmatory CT. Conclusions: Delays in patient flow through diagnostic imaging resulted in an increase in tumour size and stage, with a negative impact on prognosis of NSCLC. This information contributed to the hiring of additional CT technologists and extended CT hours to decrease the wait time for diagnostic imaging. With reduced wait times, the prognosis of NSCLC was not adversely impacted as patients navigated through diagnostic imaging.
Conclusions : Les retards dans l'acheminement des patients en imagerie diagnostique ont entraîn e une augmentation de la taille des tumeurs et un avancement du stade de la maladie, ce qui a des r epercussions n efastes sur le pronostic des personnes atteintes d'un CPNPC.
A la lumi ere de ces renseignements, on a embauch e d'autres technologues sp ecialis es en TDM et on a prolong e les p eriodes o u les TDM sont effectu ees, afin de r eduire le temps d'attente pour subir des examens d'imagerie diagnostique. La r eduction du temps d'attente a permis de ne pas aggraver le pronostic dans les cas de CPNPC tandis que les patients etaient achemin es en imagerie diagnostique. Ó 2015 Canadian Association of Radiologists. All rights reserved. The assessment and the management of wait times in cancer care are important clinical, social, and political issues [1] . There are significant efforts to monitor and improve cancer wait times in Canada [2] . Studies that examine wait times attempt to identify delays and bottlenecks in cancer care, and may aid in the development of targeted solutions [3] . Despite advances in diagnostic and therapeutic strategies in recent years, lung cancer remains one of the leading causes of morbidity and mortality in the developed world [4] . Nonesmall cell lung cancer (NSCLC) represents approximately 80% of lung cancer diagnoses and has a 5-year overall survival rate of approximately 15%. The stage at which NSCLC is diagnosed has a significant impact on anticipated 5-year survival [4] . Unlike other solid tumours (with survival rates of 60%-90% at 5 years), the survival rates for lung cancer have not been improving [1] . It is important to consider what factors may contribute to these poor outcomes. Factors that affect the prognosis of lung cancer are stage, histology, age, sex, comorbidities, and time interval between first symptom and treatment [5] . Of these risk factors, the time interval between symptoms and treatment is potentially modifiable.
The concept of ''wait times'' has been more extensively explored for breast and colorectal cancers, but studies of this type that focus on lung cancer in diagnostic imaging are less common. One large-scale systematic review by Olsson et al [6] in 2009 addressed this issue and concluded that wait times are often longer than recommended, but it is unclear if this has an impact on outcome. Some studies that have been performed have primarily focused on the timing of referrals and treatments, not on the potential delays that occur during the diagnostic imaging period [7e9]. In January 2013, the Canadian Association of Radiologists published a set of maximal wait times for computed tomography (CT) and magnetic resonance imaging (MRI) [10] . This set of recommendations is a valuable reference for Canadian institutions that perform their own clinical audit. This study will focus on diagnostic imaging wait times. The objective of this study was to examine the impact, if any, of the time periods between steps in the diagnostic pathway within the imaging department, on tumour growth and stage.
Materials and Methods
This was a retrospective cohort study designed as a clinical audit. It was conducted with patients at Eastern Health who underwent a CT-guided lung biopsy from January to December 2009 (phase I) and January to December 2011 (phase II) with the pathologic diagnosis of NSCLC. The hiring of new CT technologists and extended hours (from 8-16 hours daily) contributed to a reduction in wait time between phase I and phase II. The biopsies were performed at one of the Memorial University affiliated tertiary care centers at Eastern Health (either the Health Sciences Center or St. Clare's Hospital), both in St. John's, Newfoundland. For each member of this cohort, data were collected to identify the dates of diagnostic imaging that led to the diagnosis of NSCLC. From these dates, wait times were calculated.
Patient demographics, imaging, and disease characteristics were abstracted from both PACS (picture archiving and communication system) and the Eastern Health MediTech system. The baseline characteristics collected include age and sex. Images were obtained by using Lightspeed VCT, 64-slice CT scanner (General Electric, Milwaukee, WI). Images were viewed on lung (1500 HU, À600 HU) and mediastinal (400 HU, 50 HU) windows. The lung mass was measured according to the TMN staging guidelines [4] . By using PACS and MediTech, the dates extracted included the following: (i) date of first abnormal chest imaging (usually either a chest radiograph or CT), (ii) date of follow-up chest CT to confirm that a lung mass is present (if needed), and (iii) the date that a CT-guided lung biopsy was performed that led to the pathologic diagnosis of NSCLC. The number of days between each date was calculated as the wait time. The measurement was staged according to the T stage of the 2009 TMN classification system [4] . Tumour size and stage were outcomes in the analysis.
The inclusion criteria were subjects who underwent a CT-guided lung biopsy during the study time frame. Both sexes and all ages were included. Subjects were excluded if the pathologic diagnosis was anything other than NSCLC. In cases in which an interim CT was not required, such cases were not considered in the analyses that looked at wait time from the first image to CT. In cases in which the biopsy result was inconclusive and a repeated CT-guided lung biopsy had to be performed, the date of the biopsy that produced the diagnostic sample was the date recorded for study purposes (a missed biopsy is a source of delay).
Ethical Consideration
The data were collected from MediTech and PACS. The patient identifiers were removed once the data were collected and verified. Each case was given a study number for the purposes of the analysis, which would be his or her identifier throughout the study. Full ethical approval was granted from the human investigation committee (Memorial University) before the study commenced.
Statistical Analysis
Descriptive statistics (mean [standard deviation {SD}]) were computed for age of the cohort. Tumour size and frequency of tumour stage were calculated at each of the 3 imaging points. A paired sample t test was used to evaluate if there was a significant difference in tumour size from the first abnormal imaging to the time of biopsy. The Wilcoxon matched pairs test was used to assess if there was a significant difference in stage between the first abnormal imaging and the time of biopsy. Tumour stage is considered to be ordinal data because the difference between each stage cannot be considered equal and a nonparametric correlation (Spearman rho) was used to evaluate whether tumour stage was correlated with wait time. Spearman rho also was used to evaluate whether there was a correlation between tumour size and wait time. For all statistical analysis, the SPSS software package (SPSS Inc, Chicago, IL) was used, and P < .05 was considered significant.
Results

Phase I
Patient characteristics
In 2009, there were 187 CT-guided lung biopsies performed. Sixty-six of these specimens met the inclusion and exclusion criteria, and were analysed. The main reason for exclusion of subjects was that the final pathologic diagnosis was either inconclusive or other than NSCLC. In this phase, 42 of the patients were men and 24 were women. The mean (SD) age was 66.8 AE 7.5 years.
Wait times
The median wait time from first abnormal imaging to CTguided lung biopsy was 81 days. The median wait time from first abnormal imaging to follow-up (confirmatory CT) was 19 days, and the median wait time from confirmatory CT to CT-guided lung biopsy was 42.5 days ( Table 1) .
Impact of wait time on tumour stage
There was a statistically significant increase in tumour size from initial image to biopsy (mean difference, 0.67 cm; P < .0001). There also was a statistically significant increase in tumour stage from initial imaging to biopsy (P < .0001). In addition, there was a moderate but significant correlation in the time between the images and change in both tumour size (r ¼ 0.33, P ¼ .008) and stage (r ¼ 0.26, P ¼ .036). The percentage of patients in each T stage at all 3 imaging points in the study are displayed in Table 2 . There is a trend for the percentage of patients in each T stage to change as patients are waiting for a confirmatory CT or biopsy. The percentage of patients in lower T staging is smaller as patients wait for imaging. The percentage of patients with a change in stage from the first abnormal imaging to CT-guided biopsy is shown in Figure 1 . A total of 65.2% of subjects had no stage change, 25.8% increased 1 stage, 7.6% increased 2 stages, and 1.5% increased 3 stages.
Phase II
Because of the phase I results, 6 new CT technologists were hired, and the Eastern Health CT scanners now began operating 16 h/d (previously, 8 h/d) in an attempt to reduce wait times for diagnostic imaging. The same methods were used to restudy the patients who had a CT-guided lung biopsy at Eastern Health in 2011.
Patient characteristics
Eighty-five patients who had a CT-guided lung biopsy in 2011 met the inclusion and exclusion criteria. The main reason for exclusion of subjects was that the final pathologic diagnosis was either inconclusive or other than NSCLC. In this phase, 51 of the patients were men and 34 were women. The mean (SD) age was 68.7 AE 7.6 years.
Wait times
The median wait time from first abnormal imaging to CT-guided lung biopsy was 48 days. The median wait time from first abnormal imaging to follow-up (confirmatory CT) was 7.5 days, and the median wait time from confirmatory CT to CT-guided lung biopsy was 36 days ( Table 1) .
Impact of wait time on tumour stage
There was no statistically significant increase in tumour size (mean difference, 0.02 cm; P > .05) or stage (P > .05) from initial imaging to confirmatory CT. There still was a statistically significant increase in tumour size (mean difference, 0.28 cm; P < .0001) and stage (P < .0001) from confirmatory CT to biopsy. As well, there was a persistent statistically significant increase in tumour size (mean difference, 0.26 cm; P < .001) and stage (P < .001) from initial imaging to biopsy.
Discussion
Numerous previous studies looked at the time from symptom presentation to diagnosis and/or time from diagnosis to definitive surgical and/or radiation therapy for NSCLC. These studies have shown mixed results on the impact of wait times to diagnosis or therapy. Cheung et al [5] published an article about a retrospective cohort study on wait times and costs during the peridiagnostic period in Manitoba, Canada, from 1996-2000. This study found that, despite clinical suspicion for NSCLC, a significant number of patients waited more than 8 weeks for definitive diagnosis. They found that there was a substantial financial burden on the health care system during this period and advocated for more efficient health care delivery during the peridiagnostic period. This study did not look at the impact on prognosis and did look at all diagnostic routes, not solely CT-guided lung biopsy. Olsson et al [6] performed a systematic review on the timeliness of care in patients with NSCLC and concluded that it remains unclear whether more timely care improves outcome. Bozcuk et al [11] analysed survival of patients with NSCLC with respect to time to treatment. They concluded that hospital delay did not appear to affect survival of patients with NSCLC. This study did not take into consideration each specific source of hospital delay but rather looked at the overall time from general practitioner referral to first treatment.
Another retrospective cohort study, in Finland, examined the causes and impact of delay to diagnosis on survival [12] . Numerous causes for delay were identified, but one of the most common was that patients often underwent numerous consecutive procedures before a diagnosis of lung cancer was confirmed. Overall, the results of the study showed that long specialist and treatment delays were not correlated with worse prognosis in patients with lung cancer. However, the investigators did propose that, in patients with early stage disease, the time delay might be more critical because it may result in a situation in which a potentially curable disease becomes incurable. This study also stated that the growth of lung tumours is exponential, which means that, even if the history of tumour development is long, the growth at the time of discovery is more rapid and that long delays are likely a negative factor for the patient's prognosis [12] .
Our study demonstrated that delays in patient flow through lung imaging resulted in an overall increase in tumour size and stage. Longer wait times were positively correlated with an increase in both tumour size and stage. Thus, it can be inferred that prognosis and 5-year survival of NSCLC was reduced secondary to lengthy wait times. It was clear from phase 1 findings that wait times for diagnostic imaging at Eastern Health were far below an acceptable standard [7] , and this information was used to advocate for the reduction of wait time for CT imaging at Eastern Health. This resulted in the hiring of 6 new CT technologists and the Eastern Health CT scanners operating 16 h/d (previously 8 h/ d). The overall average wait time for urgent and nonurgent chest CT was reduced to 5 days as of April 2011 (and this has been maintained to date, May 2013). It was then demonstrated that a reduction in wait time from 19 to 7.5 days (wait time from abnormal chest radiograph to follow-up CT) resulted in no significant size or stage change. Thus, current shorter wait times are no longer associated with a change in stage as was seen in phase I.
Despite attempting to establish a rigorous study design for our study, there are limitations with the design that could not be overcome. First, this is a retrospective cohort study, and there are inherent limitations with this design. These include reliance on medical records and the limitation of an incomplete data set. Fortunately, electronic medical records made the occurrence of incomplete patient data in this study an infrequent occurrence. Second, the goal of this study was to look at wait times during the diagnostic imaging period. Although hospital resources are presumed to have the greatest impact on wait time, this study does not specifically evaluate many other factors that contribute to delay. At our institution, consultation with services such as thoracic surgery, oncology, and respirology was a major source of delay. Wait times for inpatients were much shorter than for outpatients. Other than resource issues, factors such as comorbid illness, access to transportation, patient choice, and insufficient biopsy sample for diagnosis may have also led to increased wait times. Another limitation of this study is that it only looks at 1 specific segment of wait time. In general, from the findings in this study, it could be argued that increased efficiency would translate into improved patient outcomes. However, specific evaluation of other sources of delay would help identify other potential bottlenecks in patient flow.
In summary, this study demonstrated that lengthy wait times affect the prognosis of NSCLC and that this can be prevented with improved patient flow and reduced wait times. The Canadian Association of Radiologists has developed a set of maximal wait time access targets for CT and MRI, and these recommendations are a valuable tool for a benchmark when completing a clinical audit [10, 13] .
